Evaluation of Off-Label Recombinant Activated Factor VII for Multiple Indications in Children
|
|
- Jane Mason
- 5 years ago
- Views:
Transcription
1 Evaluation of Off-Label Recombinant Activated Factor VII for Multiple Indications in Children Pamela D. Reiter, PharmD, * Robert J. Valuck, PhD, RPh, and Ruston S. Taylor, PharmD * Pediatric ICU and Trauma, The Children s Hospital; * The University of Colorado at Denver and Health Sciences Center, School of Pharmacy, Denver, Colorado; and Department of Pharmacy Christus Santa Rosa Hospital, San Antonio, Texas Despite a paucity of safety and efficacy data, the use of recombinant activated factor VII in children for off-label indications has now surpassed its use in hemophilia. A retrospective chart review was conducted of 46 subjects (age, 6.7 ± 6 years; weight, 26 ± 20 kg) who received recombinant activated factor VII for nonhemophiliac indications between January 1, 2004, and September 1, Indications for use included prevention (n = 6) or treatment (n = 40) of bleeding due to general surgery, hepatic failure, gastrointestinal bleeding, severe traumatic brain injury, bone marrow transplant, cardiac, acetaminophen overdose, and multiorgan system failure. Decreases in prothrombin time, partial thromboplastin time, and international normalized ratio were observed. No inappropriate thrombotic events were noted. Administration of recombinant activated factor VII was associated with a reduction in coagulation markers without obvious adverse thrombotic events at cost of $4189 per dose. These findings should be confirmed in a prospective trial. Key Words: NovoSeven Recombinant activated factor VII Bleeding Child. Coagulation disturbances resulting in clinically significant bleeding are common in critically ill children. These disturbances may be the result of congenital deficiencies such as hemophilia, trauma, liver failure, disseminated intravascular coagulation secondary to sepsis, shock, or closed head injury; or dilution of coagulation factors secondary to cardiopulmonary bypass surgery. Conventional treatment of these coagulation disturbances that present with bleeding episodes includes the administration of blood products such as packed red blood cells (RBC), cryoprecipitate, fresh frozen plasma (FFP), and platelet concentrates. Despite the success of these blood products, a number of problems and risks are associated with their use, including transmission of infectious diseases, anaphylactoid reactions, and alteration in serum calcium. 1-3 Address correspondence to: Pamela D. Reiter, PharmD, 1056 E. 19th Ave. Department of Pharmacy, Center for Pediatric Medicine, Campus Box 375, Denver, CO 80218; reiter.pam@tchden.org. Clinical and Applied Thrombosis/Hemostasis Vol. 13, No. 3, July DOI: / Sage Publications As an adjunct in the control of major hemorrhage, many practitioners are now using recombinant activated factor VII (rfviia; NovoSeven, Novo Nordisk Pharmaceutical, Inc, Princeton, NJ). Historically, the major clinical application of rfviia, and the only approved indication by the United States (US) Food and Drug Administration (FDA), has been in hemophiliac patients with acquired coagulation factor inhibitors. However, the use of off-label rfviia in nonhemophiliac patients has been gaining interest. To date, only small cases series and single-patient anecdotal reports have described the use of rfviia in nonhemophiliac children Administration of rfviia produces supratherapeutic concentrations of factor VIIa and promotes hemostasis by activating the extrinsic pathway of the coagulation cascade. It replaces deficient activated coagulation factor VII, which complexes with tissue factor, and may activate coagulation factor X to Xa and factor IX to IXa on the surface of activated platelets. When complexed with other factors, coagulation factor Xa converts prothrombin to thrombin, a key step in the formation of a fibrin-platelet hemostatic plug. Recombinant factor VIIa has many advantages, including fast onset 233
2 234 P. D. REITER ET AL of 10 to 20 minutes, moderate duration of effect (>6 hours), absence of coagulation system activation, no effect from circulating inhibitors, and no risk of transfusion-transmissible infections. Despite these advantages, rfviia carries the risk of inappropriate thrombotic events and is very expensive: the average wholesale price in 2006 US$ is $3000 to $4000 per dose and up to $ per treatment course. Consensus recommendations for off-label use of rfviia therapy in adults have recently been published 20 ; yet treatment strategies and guidelines in the pediatric population remain elusive. No randomized controlled trials are currently available to determine how to best use rfviia in nonhemophiliac children. We present the results of our case series, the largest pediatric series reported to date, and characterize indications, dosing schema, clinical outcomes, cost of therapy, and assessment of predictors of therapy success. METHODS This was a retrospective medical chart review of all children younger than 21 years old who required rfviia for off-label (nonhemophiliac) indications between January 1, 2004, and September 1, Subjects were identified from the pharmacy billing database at The Children s Hospital (TCH), Denver Colorado, Department of Pharmacy, Center for Pediatric Medicine. TCH is a private, nonprofit, level I regional trauma center located in a metropolitan area that serves a multistate geographic area. This study protocol was reviewed and approved by the Colorado Multiple Institutional Review Board, and informed consent from parents and subjects was not required. Data collection included patient demographics, indications for rfviia administration, dose of rfviia, interval between repeat doses of rfviia, arterial ph, and baseline platelet count and concentrations of serum creatinine, fibrinogen, and lactate. The rfviia dosing regimen was determined by the attending physician and rounded to the nearest vial size within 20% of the prescribed dose. Repeat doses were at the discretion of the attending physician(s). If available, serum concentrations of factors V, VII, and VIII were documented. To describe treatment efficacy, we compared changes in coagulation parameters, described as change from baseline to end-of-treatment, in prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR). We also attempted to calculate the change in blood volume loss after therapy. To describe adverse treatment effects, we noted any description of inappropriate thromboses within 48 hours of rfviia administration. Mortality rate was calculated at 48 hours posttherapy. Direct cost of therapy was expressed using the average wholesale price in 2006 US$. To identify the influence of age and underlying disease on treatment course(s) and outcomes, we categorized patients into subgroups of indication for rfviia administration, and neonate, infant/child, or adolescent. For the purpose of this study, neonate was defined as younger than 30 days old, an infant/ child as 30 days to 15 years old, and an adolescent as older than 15 years of age. A 2-tailed, paired Student t test was used to analyze the change in coagulation parameters from baseline to the end of rfviia therapy. Linear regression analysis was performed to determine the extent to which variation in INR and PT could be explained by selected measures, including levels of fibrinogen, whole blood lactate, arterial ph, and platelet count at start of therapy, as well as dose (expressed in micrograms, micrograms/kilogram, and number of doses administered). Forced entry regression models that included all of the above measures as predictors and stepwise regression models (in which only significant independent predictors of response are included, as determined by the statistical software) were used to fit to the data for INR and PT outcomes, and variables reaching statistical significance as predictors were identified. Pearson s correlation was used to identify any baseline factors that were associated with a lower posttreatment INR. P <.05 was considered indicative of statistically significant predictive ability or association for any given measure. All analyses were performed using SPSS 14.0 software (SPSS Inc, Chicago, IL). RESULTS During the study period, 54 patients received rfviia. Two were excluded because they received rfviia for hemophilia, leaving 52 charts for review. Six subjects were then excluded from analysis because of disparities between medication billing and drug administration documentation, leaving 46 patients for final analysis (24 girls, 22 boys). The mean age of these patients was 6.7 ± 6 years (range, 4 days 18 years), including 4 neonates, 25 infants/children, and 7 adolescents. Their mean
3 FACTOR RVIIA IN CHILDREN 235 weight was 26 ± 22 kg (range, 2-88 kg). Of these patients, 87% received rfviia as therapy for active bleeding, and 13% received therapy as prophylaxis before an invasive procedure. The underlying disease process was used to categorize patients into 9 groups: general surgery, gastrointestinal (GI) bleed, postoperative cardiac surgery, nontoxin-related hepatic failure, severe traumatic brain injury (TBI), acetaminophen (APAP) overdose, bone marrow transplantation (BMT), multiple organ failure (MOF), and prophylaxis. The clinical characteristics of the study population, as a whole and as subgroups, are summarized in Table 1. At the time of rfviia administration, all patients who were actively bleeding and half of the patients who received prophylactic therapy were coagulopathic. The provision of conventional transfusion therapy, consisting of any or all of fresh frozen platelets (FFP), red blood cells (RBC), or cryoprecipitate, was under way in 42 of 46 patients. A summary of transfusion and hemostatic treatment, along with hematologic status of the study population, is presented in Table 2. Blood loss was so perfuse in 13 patients that quantification was not possible. Subjects in the neonate and infant/child subgroups had a much higher blood loss compared with the older subjects. Patients in the GI bleed, TBI, postoperative cardiac surgery, BMT, and general surgery groups had the highest blood volume loss, whereas patients in the prophylaxis, nontoxin hepatic failure, MOF, and APAP overdose group had little to no blood loss recorded. We were not able to accurately calculate change in blood loss associated with rfviia therapy owing to inadequate documentation. Serum concentrations of factors V, VII, or VIII were available in 14 patients and were 319% ± 21.5% in 3 (normal, 63%-116%), 48% ± 50% in 14 (normal, 51%-120%), and 271.6% ± 65% in 3 (normal, 58%-132%), respectively. The dose of rfviia varied with underlying disease process (Table 3). Although the mean dose of rfviia provided to the entire study population was 111 μg/kg, the variability was wide (SD, 114 μg/kg), with between 1 and 9 doses provided per patient. Provision of additional doses was determined entirely by the attending physician. Almost half of the patients (22/46) received more than 1 rfviia dose during the study period. The time interval between doses varied from 1 hour to 6 months. When further analyzed using data during a discrete episode (within 48 hours), the interval between repeat doses was 16.8 hours (range, 1-48 hours). Laboratory markers of coagulation were documented at baseline and again at the completion of rfviia therapy for a discrete episode, except for the patient with a GI hemorrhage, whose predose coagulation markers were not obtained. A reduction in INR was observed across all groups, with statistical significance (P.05) detected in the APAP, MOF, postoperative cardiac, and prophylaxis groups (Figure 1). Likewise, a reduction in PT was observed, with significance detected in the MOF, postoperative cardiac, and prophylaxis groups (Figure 2). While a reduction in PTT was observed, it was less robust (Figure 3). There were no reports of inappropriate thromboses in any patient within 48 hours of rfviia therapy. Overall 48-hour post-rfviia therapy mortality was 35%. Mortality was the highest (at 100%) in the severe TBI and GI bleed subgroups. All deaths occurred in the treatment subgroups. Medical support was withdrawn in the each of the 3 patients in the severe TBI group because of catastrophic brain injury without likelihood of recovery. The patient in the GI bleed group was transported to TCH in extremis and died shortly after arrival. Of the 16 patients who died within 48 hours of rfviia therapy, 3 (19%) died as a direct result of acute hemorrhage and 13 (81%) from their injuries or underlying disease processes. Stepwise linear regression analysis identified whole blood lactate as a statistically significant independent predictor of posttreatment PT. That is to say, a lower whole blood lactate concentration could explain a lower (more successful) posttreatment PT (standardized coefficient β =0.502; P <.05). Variability in INR could not be predicted by any measurement tested. Pearson correlation analyses identified baseline arterial ph and baseline platelet count as factors associated with a lower posttreatment INR (see Table 4). The overall cost of rfviia therapy was $4189 ± $3106 per dose (range, $1908 $15 264) and $8574 ± $9462 (range, $1908 $50 978) per course. The patient who received the highest number of doses was in fulminate nontoxin-mediated hepatic failure and received 9 doses over 6 days. This patient ultimately received a liver transplant and survived to discharge. DISCUSSION Off-label use of rfviia in the United States has now surpassed its official FDA-approved use. In the present evaluation, 96% of subjects screened
4 TABLE 1. Baseline Characteristics of Study Population, Categorized by Indication and Patient Age a Entire General Hepatic GI APAP Study Surgery Failure Prophylaxis Bleed TBI BMT Cardiac OD MOF Neonate Infant/Child Adolescent Characteristic (n = 46) (n = 2) (n = 9) (n = 6) (n = 1) (n = 3) (n = 5) (n = 11) (n = 3) (n = 6) (n = 4) (n = 35) (n = 7) Age (yr) 6.7 (6) 13.5 (3.5) 4.6 (5) 5.8 (5.3) (1.3) 8.6 (6.6) 4.6 (5.7) 15 (1) 9.5 (7.2) 0.03 (0.01) 5.6 (5) 15.7 (1.1) Weight (kg) 26 (22) 28.7 (14) 25 (27) 22.6 (17) (5) 24.5 (14) 21.7 (26) 58.4 (20) 30.2 (24) 2.99 (0.97) 22.3 (18) 57 (20) Vitamin K % Receiving Dose (mg) 2.8 (3) (1.7) 4.9 (2.8) NA 3 b 2 (2.2) 1.6 (3) 6.7 (2.9) 2.6 (2.3) 1.3 (0.6) 2.6 (2.7) 5.2 (4.3) Arterial ph c 7.3 (0.2) 7.29 (0.16) 7.3 (1.3) 7.4 (0.1) (0.27) 7.4 (0.1) 7.45 (0.1) 7.36 (0.04) 7.28 (0.14) 7.38 (0.13) 7.35 (0.18) 7.32 (0.18) WB lactate d 5.6 (6.7) NA 5.2 (3.9) 5.3 (5.2) NA NA 1.6 b 3.8 (2.8) 9 b 0.94 b 9.36 (0.48) 3.5 (2.8) NA GI = gastrointestinal; TBI = traumatic brain injury; BMT = bone marrow transplant; APAP OD = acetaminophen overdose; MOF = multiple organ failure; WB = whole blood; NA = not available. a. Data are presented as mean (standard deviation). b. Single data point. c. Normal reference range, d. Normal reference range,
5 TABLE 2. Transfusion Requirements, Hemostatic Therapy, and Hematologic Status of Study Population a Entire General Hepatic GI APAP Study Surgery Failure Prophylaxis Bleed TBI BMT Cardiac OD MOF Neonate Infant/Child Adolescent (n = 46) (n = 2) (n = 9) (n = 6) (n = 1) (n = 3) (n = 5) (n = 11) (n = 3) (n = 6) (n = 4) (n = 35) (n = 7) FFP (ml/kg) 50 (59) 17 (11) 48 (44) (15) 11 (21) 107 (21) 42 (51) 23 (25) 123 (82) 48 (55) 12 (8) FFP doses/ patient (n) 1.8 (1.5) (2.3) 1.5 (0.5) (0.6) 0.5 (1) 1.5 (0.7) 2.3 (1.5) 1.5 (1.9) 2 (1) 1.7 (1.6) 1.8 (1.7) Hct (mg/dl) At baseline 31.3 (9.4) 35.5 (3.5) 32.6 (8) 28.5 (6.5) (10.2) 27.3 (7.8) 36.9 (9.8) 42.8 (7.5) 25 (5.9) 30.1 (9.5) 30.7 (9.3) 34.7 (10.8) At end of therapy 31.3 (7) 31 b 30.8 (9.7) 29.3 (7.2) NA 28.8 (1) 26.3 (3) 34.6 (5.8) 38.1 (4) 31.2 (7.5) 35.2 (1.8) 30.2 (6.7) 36.6 (9) Cryo (ml/kg) 2.6 (5.3) b 2.4 (4) (11) 6.2 (7) ( (8.9) 2.54 (5.2) 0.8 (1.9) Fibrinogen before 276 (166) 245 (248) 207 (106) 234 (40) 250 b 122 (90) 377 (192) 320 (105) 275 (180) 359 (306) 220 (66) 265 (149) 404 (233) rfviia therapy Platelet count ( 10 mm 3 ) 150 (102) 85.5 (22) 138 (124) 164 (54) (50) 63 (43) 198 (101) 222 (144) 68 (39) 229 (91) 136 (94) 177 (131) RBC Loss (ml) TMTC (n = 13) (138) 18.3 (28) b TMTC TMTC 0 5 b TMTC TMTC 0 (n = 4) 754 (1192) (2121) n = 3 n = 2 (n = 3) (n = 10) (n = 9) b 1485 b 604 (529) (2505) Infused (ml/kg) 72 (101) 71 (78) 37 (47) 13 (20) (12) 61 (55) 176 (144) 4 (7) 14 (15) 176 (142) 74 (96) 4.78 (6.4) GI = gastrointestinal; TBI = traumatic brain injury; BMT = bone marrow transplant; APAP OD = acetaminophen overdose; MOF = multiple organ failure; FFP = fresh frozen plasma; Hct = hematocrit; Cryo = cryoprecipitate; rfviia = recombinant activated factor VII; RBC = red blood cell; TMTC = too much to count; NA = not available. a. Data presented as mean (standard deviation). b. Single data point. 237
6 238 P. D. REITER ET AL TABLE 3. Summary of Recombinant Activated Factor VII Dosing a Entire General Hepatic GI APAP Study Surgery Failure Prophylaxis Bleed TBI BMT Cardiac Overdose MOF (n = 46) (n = 2) (n = 9) (n = 6) (n = 1) (n = 8) (n = 5) (n = 11) (n = 3) (n = 6) Dose (μg) (2082) (2546) (2151) (1533) (693) (1368) (2968) (794) (2169) Dose (μg/kg) 111 (114) 94 (43.8) 89 (22) 74 (15) (30) 141 (42) 160 (225) 73 (28) 89 (7) Doses per 2.1 (1.7) (2.3) 1.2 (0.4) (0.6) 3.4 (1.8) 1.6 (1.5) 2.3 (1.5) 1.3 (0.5) patient (n) GI = gastrointestinal; TBI = traumatic brain injury; BMT = bone marrow transplant; APAP= acetaminophen; MOF = multiple organ failure. a. Dosing data are presented as mean (standard deviation). FIG. 1. Effect of recombinant activated factor VII (rfviia) on the international normalized ratio (INR). BMT = bone marrow transplantation; MOF = multiple organ failure; APAP = acetaminophen overdose; TBI = traumatic brain injury. *P <.05. FIG. 3. Effect of recombinant activated factor FVII (rfviia) on partial thromboplastin time (PTT). BMT = bone marrow transplantation; MOF = multiple organ failure; APAP = acetaminophen overdose; TBI = traumatic brain injury. *P <.05. for study inclusion received rfviia for off-label (nonhemophiliac) indications. This study highlights the indications, clinical outcomes, predictive factors of therapy success, and cost associated with FIG. 2. Effect of recombinant activated factor FVII (rfviia) on prothrombin time (PT). BMT = bone marrow transplantation; MOF = multiple organ failure; APAP = acetaminophen overdose; TBI = traumatic brain injury. *P <.05. off-label use of rfviia in children. Previous anecdotal case reports and small studies of rfviia in nonhemophiliac infants and children have demonstrated efficacy in cardiac surgery, BMT, 13 inherited platelet function disorders, 4,8,14 Burkitt s lymphoma, 18 life-threatening hemorrhage in Dengue shock syndrome 6 and in neonates, 15,19 global coagulation dysfunction, 9 and liver failure. 7 With the exception of a report 5 in which 28 patients were followed up, all the reports consisted of 1 to 15 patients. These early reports were critical in establishing a role for rfviia outside of hemophilia. We now report data from the largest pediatric case series to date and underscore the increased use of rfviia for bleeding triggered by trauma, surgery, MOF, BMT, and liver disease. The 2 largest subgroups described in this report included children with acute or chronic liver failure and postcardiopulmonary bypass patients. Treatment algorithms, under the premise of goal-directed therapy, for bleeding after pediatric cardiopulmonary bypass
7 FACTOR RVIIA IN CHILDREN 239 TABLE 4. Pearson Correlation Matrix Baseline Posttreatment Posttreatment RFVIIa Dose No. Doses Arterial Whole Blood Platelet PT INR (μg/kg) Infused ph Lactate Fibrinogen Count Posttreatment PT ** Posttreatment INR ** * * rfviia dose (μg/kg) No. doses infused Baseline arterial ph * Baseline whole blood * lactate Baseline fibrinogen Baseline platelet count * * rfviia = recombinant activated factor VII. *P <.05. **P <.001. have been proposed and encourage the use of platelet transfusions, FFP, cryoprecipitate, aprotinin, and 1-desamino- 8-D-arginine vasopressin before using rfviia. All of the patients within the cardiac subgroup of the current study received FFP, cryoprecipitate, and platelets before rfviia. Efficacy in our study was measured predominately by change in PT, INR, and PTT coagulation markers from baseline to the end of rfviia therapy. All these markers of coagulation fell after therapy, with significant reductions noted in specific diagnostic subgroups. The decline in PTT was less profound and was not surprising given the mechanism of action of rfviia on the extrinsic coagulation pathway. Although attempts were made to include hemostasis or change in blood volume loss as an additional marker of therapy effectiveness, the retrospective nature (and hence incomplete documentation) of this study did not consistently allow for this type of comparison. The mortality at 48 hours post-rfviia, which was a mean 35% and varied with clinical diagnosis (range, 0%-100%), was lower than the 49% to 55% mortality rates reported in adults. 20 The most common cause of death in our study population was not hemorrhagic in nature but rather was due to the child s injuries or the underlying disease process. Because rfviia is an expensive therapy, investigators have tried to identify groups of patients in which clinical benefit is most likely. Specific factors in adults associated with a reduction in rfviia effectiveness include profound acidosis and low levels of platelets and fibrinogen. 21,22 We hoped to identify baseline predictive factors in children to help distinguish futile administration from effective administration. However, stepwise linear regression analysis identified only the variable of whole blood lactate that independently predicted a reduction in PT. Pearson correlation analyses only identified the 2 factors of platelet count and arterial ph at baseline as being associated with a lower posttreatment INR. From this data pool, it therefore appears that prediction of clinical benefit from rfviia is more difficult in children than adults. Overall cost of treatment with rfviia in this study group was $8574 ± $9462 (range, $1908- $50 978) per course. This exorbitant cost, coupled with a lack of firm pediatric prescribing guidelines, has prompted some US hospitals to create a drug gatekeeper. This gatekeeper, who is generally a medical or pharmacy director, is responsible for reviewing all orders before dispensing. After review, the gatekeeper judges the order as acceptable or unacceptable; however, this practice may require some lead time and thus may not be suitable for a medication such as rfviia owing to its urgent nature. Fortunately, overall clinical use of rfviia during the study period at our institution appeared to be appropriate, because most patients were aggressively treated with conventional therapy (RBC, cryoprecipitate, FFP, and platelet concentrates) before rfviia administration. We did identify 2 types of patient that may not benefit from the addition of rfviia. These are (1) a child who arrives at the hospital in extremis with profound acidosis and anemia due to bleeding and (2) a child who has sustained obvious catastrophic brain injury and in whom withdrawal of life support is likely.
8 240 P. D. REITER ET AL CONCLUSIONS The overall benefits of rfviia are difficult to estimate without the support of a randomized, prospective clinical trial. Although the results of this report do not satisfy the criteria necessary to establish unequivocal safety and efficacy recommendations, the data do reflect current clinical practice and suggest that the administration of rfviia in children for nonhemophilic indications is associated with a reduction in laboratory bleeding indices and does not appear to result in inappropriate thrombotic events. In an effort to further elucidate the best role of rfviia in children, we believe that prospective clinical trials should be performed and reported, and that ultimately, a consensus guideline with specific administration criteria should be developed for children. REFERENCES 1. Dodd RY. Emerging infections, transfusion safety, and epidemiology. N Engl J Med. 2003;349: Pealer LN, Marfin AA, Petersen LR, et al; West Nile Transmission Investigation Team. Transmission of West Nile virus through blood transfusion in the United States in N Engl J Med. 2003;349: Taylor RW, O Brien J, Trottier SJ, et al. Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care Med. 2006;34: Hennewig U, Laws HJ, Eisert S, Gobel U. Bleeding and surgery in children with Glanzman thrombasthenia with and without the use of recombinant factor VIIa. Klin Padiatr. 2005;217: Kalicinski P, Markiewicz M, Kaminski A, et al. Single pretransplant bolus of recombinant activated factor VII ameliorates influence of risk factors for blood loss during orthotopic liver transplantation. Pediatr Transplant. 2005; 9: Chuansumrit A, Tangnararatchakit K, Lektakul Y, et al. The use of recombinant activated factor VII for controlling lifethreatening bleeding in Dengue shock syndrome. Blood Coagul Fibrinolysis. 2004;15: Brown JB, Emerick KM, Brown DL, Whitington PF, Alonso EM Recombinant factor VIIa improves coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr. 2003;37: Almeida AM, Khair K, Hann I, Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol. 2003;121: Tobias JD, Groeper K, Berkenbosch JW. Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric patients. South Med J. 2003;96: Pychynska-Pokorska M, Moll JJ, Krajewski W, Jarosik P. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care. 2004; 5: Tobias JD, Berkenbosch JW, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med. 2003;4: Egan JR, Lammi A, Schell DN, Gillis J, Nunn GR. Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med. 2004;30: Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D. Off-label use of recombinant factor VIIa following bone marrow transplantation. Bone Marrow Transplant. 2001;28: Yilmaz BT, Alioglu B, Ozyurek E, Akay HT, Mercan S, Ozbek N.. Sucessful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia. Pediatr Cardiol. 2005; 26: Veldman A, Fischer D, Voigt B, et al. Life-threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med. 2002;28: Razon Y, Erez E, Vidne B, et al. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Paediatr Anaesth. 2005;15: Cetin H, Yalaz M, Akisu M, Karapinar DY, Kavakli K, Kultursay N. The use of recombinant activated factor VII in the treatment of massive pulmonary hemorrhage in a preterm infant, Blood Coagul Fibrinolysis. 2006;17: Culic S. Kuljis D, Armanda V, Jankovic S. Successful management of bleeding with recombinant factor VIIa (NovoSeven ) in a patient with Burkitt lymphoma and thrombosis of the left femoral and left common iliac veins. Pediatr Blood Cancer Mar2; Epub ahead of print. 19. Tancabelic J, Haun SE. Management of coagulopathy with recombinant factor VIIa in a neonate with echovirus type 7. Pediatr Blood Cancer. 2004;43: Shander A, Goodnough LT, Ratko T, et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven ) therapy. Pharma Ther. 2005;30: Stein DM, Dutton RP, O Connor J, et al. Determinants of futility of administration of recombinant factor VIIa in trauma. J Trauma. 2005:59; Meng ZH, Wolberg AS, Monroe DM, Hoffman M. The effect of temperature and ph on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma. 2003;55:
Recombinant Factor VIIa in Pediatric Patients
( TATM 2003;5(5 Suppl):40-45 Recombinant Factor VIIa in Pediatric Patients JOSEPH D. TOBIAS, MD VICE-CHAIRMAN, DEPARTMENT OF ANESTHESIOLOGY CHIEF, PEDIATRIC CRITICAL CARE/PEDIATRIC ANESTHESIOLOGY RUSSELL
More informationRecombinant Activated Factor VII: Useful. Department of Surgery Grand Rounds 11/8/10 David Mauchley MD
Recombinant Activated Factor VII: Useful Department of Surgery Grand Rounds 11/8/10 David Mauchley MD Hemostasis and Coagulation Traditional cascade model Two convergent pathways Series of proteolytic
More informationUse of Recombinant Factor VIIa (NovoSeven) in Pediatric Cardiac Surgery
The Journal of ExtraCorporeal Technology Use of Recombinant Factor VIIa (NovoSeven) in Pediatric Cardiac Surgery Scott D. Niles, BA, CCP;* Harold M. Burkhart, MD;* David A. Duffey, BS, BSN, CCP;* Keri
More informationBleeding, Coagulopathy, and Thrombosis in the Injured Patient
Bleeding, Coagulopathy, and Thrombosis in the Injured Patient June 7, 2008 Kristan Staudenmayer, MD Trauma Fellow UCSF/SFGH Trauma deaths Sauaia A, et al. J Trauma. Feb 1995;38(2):185 Coagulopathy is Multi-factorial
More informationApproach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate
Approach to bleeding disorders &treatment by RAJESH.N General medicine post graduate 2 Approach to a patient of bleeding diathesis 1. Clinical evaluation: History, Clinical features 2. Laboratory approach:
More informationBlood Transfusion Guidelines in Clinical Practice
Blood Transfusion Guidelines in Clinical Practice Salwa Hindawi Director of Blood Transfusion Services Associate Professor in Haematology and Transfusion Medicine King Abdalaziz University, Jeddah Saudi
More informationTransfusion Requirements and Management in Trauma RACHEL JACK
Transfusion Requirements and Management in Trauma RACHEL JACK Overview Haemostatic resuscitation Massive Transfusion Protocol Overview of NBA research guidelines Haemostatic resuscitation Permissive hypotension
More informationUse of Prothrombin Complex Concentrates (PCC) CONTENTS
CONTENTS Page 1: Exclusion Criteria and Approved Indications for Use Page 2: Dosing / Administration / Storage Page 4: Prescribing / Monitoring / Dispensing Page 5: Cautions / Warnings / Cost Analysis
More informationProthrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
More informationMASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE
MASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE CONTENTS Definition Indications Transfusion trigger Massive transfusion protocol Complications DEFINITION Massive transfusion:
More informationRecombinant Activated Factor VII in Controlling Bleeding in Non-Hemophiliac Patients
Bahrain Medical Bulletin, Vol. 34, No. 3, September 2012 Recombinant Activated Factor VII in Controlling Bleeding in Non-Hemophiliac Patients Ali A Faydhi, MRCP, EDIC* Adel M Al-Shabassy, MD** Yasser A
More informationGUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS
CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA Introduction: GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS These guidelines have been developed in conjunction with the hospital Transfusion Committee.
More informationEffective Date: Approved by: Laboratory Director, Jerry Barker (electronic signature)
1 of 5 Policy #: 702 (PHL-702-05) Effective Date: 9/30/2004 Reviewed Date: 8/1/2016 Subject: TRANSFUSION GUIDELINES Approved by: Laboratory Director, Jerry Barker (electronic signature) Approved by: Laboratory
More informationMajor Haemorrhage Protocol. Commentary
Hairmyres Hospital Monklands Hospital Wishaw General Hospital Major Haemorrhage Protocol Commentary N.B. There is a separate NHSL protocol for the Management of Obstetric Haemorrhage Authors Dr Tracey
More informationRecombinant Factor Seven Therapy for Postoperative Bleeding in Neonatal and Pediatric Cardiac Surgery
Recombinant Factor Seven Therapy for Postoperative Bleeding in Neonatal and Pediatric Cardiac Surgery Hemant S. Agarwal, MBBS, Jo E. Bennett, BS, Kevin B. Churchwell, FAAP, MD, Karla G. Christian, MD,
More informationAdult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol
Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor
More informationMassive transfusion: Recent advances, guidelines & strategies. Dr.A.Surekha Devi Head, Dept. of Transfusion Medicine Global Hospital Hyderabad
Massive transfusion: Recent advances, guidelines & strategies Dr.A.Surekha Devi Head, Dept. of Transfusion Medicine Global Hospital Hyderabad Massive Hemorrhage Introduction Hemorrhage is a major cause
More informationAgent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes ~ 100 units Heparin neutralization in ~ 5 min
Nanik (Nayri) Hatsakorzian Pharm.D/MPH candidate 2014 Touro University College of Pharmacy CA Bleeding Reversal Agents Agent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes
More informationCoagulation, Haemostasis and interpretation of Coagulation tests
Coagulation, Haemostasis and interpretation of Coagulation tests Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect
More informationCoagulopathy: Measuring and Management. Nina A. Guzzetta, M.D. Children s Healthcare of Atlanta Emory University School of Medicine
Coagulopathy: Measuring and Management Nina A. Guzzetta, M.D. Children s Healthcare of Atlanta Emory University School of Medicine No Financial Disclosures Objectives Define coagulopathy of trauma Define
More informationThromboelastography Use in the Perioperative Transfusion Management of a Patient with Hemophilia A Undergoing Liver Transplantation
Open Journal of Organ Transplant Surgery, 2013, 3, 13-17 http://dx.doi.org/10.4236/ojots.2013.31003 Published Online February 2013 (http://www.scirp.org/journal/ojots) Thromboelastography Use in the Perioperative
More informationTRANSFUSIONS FIRST, DO NO HARM
TRANSFUSIONS FIRST, DO NO HARM BECAUSE BLOOD CAN KILL 7 TRALI DEATHS SINCE 2002 WMC 5 women BECAUSE In OB you are transfusing 2 instead of 1 BECAUSE BLOOD IS A LIQUID TRANSPLANT RISKS versus BENEFITS versus
More informationUse of Prothrombin Complex Concentrate to Reverse Coagulopathy Rio Grande Trauma Conference
Use of Prothrombin Complex Concentrate to Reverse Coagulopathy Rio Grande Trauma Conference John A. Aucar, MD, MSHI, FACS, CPE EmCare Acute Care Surgery Del Sol Medical Center Associate Professor, University
More informationDr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN
Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN The student should be able:» To identify the mechanism of homeostasis and the role of vessels, platelets
More informationTRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006
TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 CTU blood product transfusion guidelines 2006 1 Summary of guidelines RED CELLS (10-15ml/kg) This applies to ward patients / icu patients who are stable.
More informationMANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR
MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma
More informationStudy design: Multicenter, randomized, controlled, cross-over, blinded PK comparison
Brand Name 1, 2 : Rixubis Generic Name 1, 2 : Coagulation factor IX recombinant Manufacturer 5 : Baxter Drug Class 1, 2, 3 : Antihemophilic agent Labeled Uses 1, 2 : Hemophilia B hemorrhage, routine prophylaxis,
More informationLifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA Transfusion Criteria Version#2 POLICY NO.
LifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA 1011.02 Transfusion Criteria Version#2 Department POLICY NO. PAGE NO. Blood Bank Quality Assurance Manual
More informationRecombinant factor VIIa: Hype or hope? Jed Gorlin MD, MBA
Recombinant factor VIIa: Hype or hope? Jed Gorlin MD, MBA Goals of presentation Challenge current use of rviia using data Review how rviia works Approved indications Review results of randomized trials
More informationHow can ROTEM testing help you in cardiac surgery?
How can ROTEM testing help you in cardiac surgery? Complicated bleeding situations can appear intra and post operatively. They can be life-threatening and always require immediate action. A fast differential
More informationADMINISTRATIVE CLINICAL Page 1 of 6
ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15
More informationCoagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU
Coagulation Disorders Dr. Muhammad Shamim Assistant Professor, BMU 1 Introduction Local Vs. General Hematoma & Joint bleed Coagulation Skin/Mucosal Petechiae & Purpura PLT wound / surgical bleeding Immediate
More informationBlood Components & Indications for Transfusion. Neda Kalhor
Blood Components & Indications for Transfusion Neda Kalhor Blood products Cellular Components: Red blood cells - Leukocyte-reduced RBCs - Washed RBCs - Irradiated RBCs Platelets - Random-donor platelets
More informationBLEEDING DISORDERS. JC Opperman 2012
BLEEDING DISORDERS JC Opperman 2012 Primary and Secondary Clotting Laboratory Tests Routine screening tests Prothrombin time (PT) (INR) increased in neonates (12-18 sec) Partial thromboplastin time (PTT)
More informationEMSS17: Bleeding patients course material
EMSS17: Bleeding patients course material Introduction During the bleeding patients workshop at the Emergency Medicine Summer School 2017 (EMSS17) you will learn how to assess and treat bleeding patients
More informationWhen should I transfuse platelets and plasma for children? Dr Liz Chalmers. Consultant Paediatric Haematologist Royal Hospital for Children Glasgow
When should I transfuse platelets and plasma for children? Dr Liz Chalmers Consultant Paediatric Haematologist Royal Hospital for Children Glasgow When should I transfuse platelets and plasma in children?
More informationChapter 1 The Reversing Agents
Available Strategies to Reverse Anticoagulant Medications Michael L. Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Objectives: Describe the pharmacological agents
More informationRecombinant factor VIIa: safety and efficacy Lawrence T. Goodnough a and Aryeh S. Shander b,c
Recombinant factor VIIa: safety and efficacy Lawrence T. Goodnough a and Aryeh S. Shander b,c Purpose of review Recombinant factor VIIa has been increasingly used to provide hemostasis in nonapproved indications.
More informationBlood Component Therapy
Blood Component Therapy Dr Anupam Chhabra Incharge-Transfusion Medicine Pushpanjali Crosslay Hopital NCR-Delhi Introduction Blood a blood components are considered drugs because of their use in treating
More informationAppendix 3 PCC Warfarin Reversal
Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin
More informationBleeding Disorders. Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph
Bleeding Disorders Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph Normal hemostasis The normal hemostatic response involves interactions among: The blood vessel wall (endothelium)
More informationReversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
More informationShock and Resuscitation: Part II. Patrick M Reilly MD FACS Professor of Surgery
Shock and Resuscitation: Part II Patrick M Reilly MD FACS Professor of Surgery Trauma Patient 1823 / 18 Police Dropoff Torso GSW Lower Midline / Right Buttock Shock This Monday Trauma Patient 1823 / 18
More informationMANAGEMENT OF COAGULOPATHY AFTER TRAUMA OR MAJOR SURGERY
MANAGEMENT OF COAGULOPATHY AFTER TRAUMA OR MAJOR SURGERY 19th ANNUAL CONTROVERSIES AND PROBLEMS IN SURGERY Thabo Mothabeng General Surgery: 1 Military Hospital HH Stone et al. Ann Surg. May 1983; 197(5):
More informationDisseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS
به نام خدا Disseminated Intravascular Coagulation M.Bahmanpour MD Assistant professor IUMS Algorithm for Diagnosis of DIC DIC Score factor score Presence of known underlying disorder No= 0 yes=2 Coagolation
More informationNOVO NORDISK A/S. 250 KIU/vial), 1 mg/ml after reconstitution
08-15 NovoSeven NOVO NORDISK A/S 1 mg, 2 mg and 5 mg powder and solvent for solution for injection Qualitative and quantitative composition eptacog alfa (activated) 1 mg/vial (corresponds to 50 KIU/vial),
More informationJohn Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne
John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne Overview of coagulation Testing coagulation Coagulopathy in ICU Incidence Causes Evaluation Management Coagulation
More informationRecombinant Factor VIIa for Intracerebral Hemorrhage
Recombinant Factor VIIa for Intracerebral Hemorrhage January 24, 2006 Justin Lee Pharmacy Resident University Health Network Outline 1. Introduction to patient case 2. Overview of intracerebral hemorrhage
More informationEXCESSIVE BLEEDING IS A common complication of
The Utility of Thromboelastography for Guiding Recombinant Activated Factor VII Therapy for Refractory Hemorrhage After Cardiac Surgery Marcin Wąsowicz, MD,* Massimiliano Meineri, MD,* Stuart M. McCluskey,
More informationEmergency Blood and Massive Transfusion: The Surgeon s Perspective. Transfusion Medicine Update September 16 17, 2009
Transfusion Medicine Update September 16 17, 2009 Mandip S. Atwal, D.O. FACOS Carl M. Pesta, D.O. FACOS Agenda History Hemorrhagic shock Transfusion is Bad Transfusion Prevention Transfusion The Red Chest
More informationADULT TRANSFUSION GUIDELINES ORDERED COMPONENT
ADULT TRANSFUSIN GUIDELINES RDERED Packed red cells (RBCs) RBCs, WBCs, platelets & plasma (minimal) Increase red cell mass and oxygen carrying capacity; generally indicated when Hgb is 7 gm or Hct 21 unless
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN PROTHROMBIN COMPLEX PRODUCTS (CPMP/BPWG/3735/02)
European Medicines Agency Human Medicines Evaluation Unit London, 21 October 2004 Corrigendum, 18 November 2004 CPMP/BPWG/3735/02 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN
More informationBLEEDING DISORDERS Simple complement:
BLEEDING DISORDERS Simple complement: 1. Select the statement that describe the thrombocytopenia definition: A. Marked decrease of the Von Willebrandt factor B. Absence of antihemophilic factor A C. Disorder
More informationSuccessful Treatment of Intractable Hemothorax with Recombinant Factor VIIa in a Nonhemophilic Patient
CASE REPORT Successful Treatment of Intractable Hemothorax with Recombinant Factor VIIa in a Nonhemophilic Patient Yu-Feng Wei, 1,3 Chao-Chi Ho, 1, * Ming-Tzer Lin, 1 Ang Yuan, Chong-Jen Yu 1 Recombinant
More informationRecombinant Treatments for Bleeding Disorders. An overview of treatments that are considered to have a low risk of viral transmission
Recombinant Treatments for Bleeding Disorders An overview of treatments that are considered to have a low risk of viral transmission History of bleeding disorder treatments Recombinant products: A significant
More informationThromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIa
ORIGINAL CONTRIBUTION Thromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIa Kathryn A. O Connell, MD, PhD Jennifer J. Wood, PhD, MPH Robert P. Wise, MD, MPH Jay N. Lozier,
More informationCrackCast Episode 7 Blood and Blood Components
CrackCast Episode 7 Blood and Blood Components Episode Overview: 1) Describe the 3 categories of blood antigens 2) Who is the universal donor and why? 3) Define massive transfusion 4) List 5 physiologic
More informationResuscitation Update
Resuscitation Update? Dr. Edward Pyun Jr., M.D. FACS Trauma Medical Director/Surgical ICU Director OSF St. Anthony Medical Center Trauma Services Perryville Surgical Associates November 10, 2012 2009 Recommendations
More informationHematology Review. CCRN exam. The Coagulation Cascade. The Coagulation Cascade. Components include: Intrinsic pathway Extrinsic pathway Common pathway
CCRN exam Hematology Review CCRN Review October 2013 Department of Critical Care Nursing Hematology is 2% of the exam Focus on coagulation cascade, DIC, and HIT Anatomy of the hematologic system Bone marrow
More informationthe bleeding won t stop? Liane Manz RN, BScN, CNCC(c) Royal Alexandra Hospital
What do you do when the bleeding won t stop? Teddie Tanguay RN, MN, NP, CNCC(c) Teddie Tanguay RN, MN, NP, CNCC(c) Liane Manz RN, BScN, CNCC(c) Royal Alexandra Hospital Outline Case study Normal coagulation
More informationACQUIRED COAGULATION ABNORMALITIES
ACQUIRED COAGULATION ABNORMALITIES ACQUIRED COAGULATION ABNORMALITIES - causes 1. Liver disease 2. Vitamin K deficiency 3. Increased consumption of the clotting factors (disseminated intravascular coagulation
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Appropriate and Inappropriate Use of Fresh Frozen Plasma (FFP) and Packed Cell Volume (PCV)
More informationPediatric massive transfusion protocols
University of New Mexico UNM Digital Repository Emergency Medicine Research and Scholarship Emergency Medicine 2014 Pediatric massive transfusion protocols Ramsey Tate Follow this and additional works
More informationClinical Overview of Coagulation Testing Issues
Clinical Overview of Coagulation Testing Issues Adam M. Vogel, MD Assistant Professor, Division of Pediatric Surgery Washington University in St. Louis School of Medicine September 19, 2014 Disclosure
More informationMy Bloody Talk. Dr Ben Turner MBBS, FANZCA, FCICM The Royal Children s Hospital, Melbourne
My Bloody Talk Dr Ben Turner MBBS, FANZCA, FCICM The Royal Children s Hospital, Melbourne Disclosures No conflicts of interest Interest in conflict Blood transfusion Massive transfusion definitions Transfusion
More information"DENTAL MANAGEMENT OF A PATIENT TAKING ANTICOAGULANTS"
"DENTAL MANAGEMENT OF A PATIENT TAKING ANTICOAGULANTS" ------------------------------------------------------------------------ LT J.D. Molinaro, DC, USN 11 August 2000 Introduction Any patient receiving
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationGuidelines for the management of warfarin reversal in adults
SharePoint Location Clinical Policies and Guidelines SharePoint Index Directory General Policies and Guidelines Sub Area Haematology and Transfusion Key words (for search purposes) Warfarin, Bleeding Central
More informationApproach to disseminated intravascular coagulation
Approach to disseminated intravascular coagulation Khaire Ananta Shankarrao 1, Anil Burley 2, Deshmukh 3 1.MD Scholar, [kayachikitsa] 2.Professor,MD kayachikitsa. 3.Professor and HOD,Kayachikitsa. CSMSS
More informationBleeding and Haemostasis. Saman W.Boskani HDD, FIBMS Maxillofacial Surgeon
Bleeding and Haemostasis Saman W.Boskani HDD, FIBMS Maxillofacial Surgeon 1 Beeding Its escaping or extravasation of blood contents from blood vessels Types: - Arterial - Venous - Capillary Differences
More informationAmerican hospitals crawling towards Electronic Medical Records (EMR) and Computerized Physician Order Entry (CPOE)
Welcome! American hospitals crawling towards Electronic Medical Records (EMR) and Computerized Physician Order Entry (CPOE) Still
More informationRisk of ID transmission. Patient Blood Management - Blood Safety and Component Utilization. Transfusion and Cancer 4/9/2014
Patient Blood Management - Blood Safety and Component Utilization Lowell Tilzer M.D. Pathology and Lab Medicine Kansas University Med Center Risk of ID transmission Pre NAT Post NAT HIV 1:607,000 ~1:2.5
More information2012, Görlinger Klaus
Gerinnungsmanagement der Gegenwart - wie gehen wir heute vor? 25. Allander Gerinnungsrunde am 15. März 2012 Klaus Görlinger Universitätsklinikum Essen klaus@goerlinger.net CSL Behring GmbH Octapharma AG
More informationRoutine preoperative coagulation tests: are they necessary?
Routine preoperative coagulation tests: are they necessary? Dr Azzah Alzahrani MD Pediatrics Hematology /Oncology PSMMS Outline Introduction. Brief review of hemostatic mechanisms. A clinical aspect of
More informationWhat s in the Massive Transfusion Protocol (MTP) Package?
What s in the Massive Transfusion Protocol (MTP) Package? The Massive Transfusion Protocol Package is a set of documents intended to improve the coordination of a Massive Transfusion Protocol. The kit
More informationNew Strategies in the Management of Patients with Severe Sepsis
New Strategies in the Management of Patients with Severe Sepsis Michael Zgoda, MD, MBA President, Medical Staff Medical Director, ICU CMC-University, Charlotte, NC Factors of increases in the dx. of severe
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abdominal tumors, in children, 530 531 Alkalinization, in tumor lysis syndrome, 516 Allopurinol, in tumor lysis syndrome, 515 Anaphylaxis, drug
More informationDOSAGE AND ADMINISTRATION For intravenous bolus injection only Bleeding Episodes (2.1) Peri-operative Management (2.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NovoSeven RT safely and effectively. See full prescribing information for NovoSeven RT. NovoSeven
More informationIntroduction to coagulation and laboratory tests
Introduction to coagulation and laboratory tests Marc Jacquemin Special Haemostasis Laboratory Center for Molecular and Vascular Biology University of Leuven Coagulation in a blood vessel: fibrin stabilises
More informationPrevention of bleeding in surgical interventions or invasive procedures in congenital FVII deficiency (1.4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NovoSeven RT safely and effectively. See full prescribing information for NovoSeven RT. NovoSeven
More informationBlood Product Utilization A Mythbusters! Style Review. Amanda Haynes, DO 4/28/18
Blood Product Utilization A Mythbusters! Style Review Amanda Haynes, DO 4/28/18 Objectives Describe concepts in Patient Blood Management Review common misconceptions surrounding blood transfusion Summarize
More informationDefine Shock, mostly as it relates to bleeding Options and evidence for tools of resuscitation Understand a little about coagulation and coagulopathy
Define Shock, mostly as it relates to bleeding Options and evidence for tools of resuscitation Understand a little about coagulation and coagulopathy 1:1:1 New advances Reduced perfusion of vital organs
More informationUPDATE OF NEUROCRITICAL CARE PHARMACOTHERAPY. Vera Wilson, PharmD, BCPS Emergency Services Clinical Pharmacy Specialist Johnson City Medical Center
UPDATE OF NEUROCRITICAL CARE PHARMACOTHERAPY Vera Wilson, PharmD, BCPS Emergency Services Clinical Pharmacy Specialist Johnson City Medical Center DISCLOSURE STATEMENT OF FINANCIAL INTEREST I, Vera Wilson,
More informationHow can ROTEM testing help you in trauma?
How can ROTEM testing help you in trauma? Complicated bleeding situations can appear intra and post operatively. They can be life-threatening and always require immediate action. A fast differential diagnosis
More informationConsent Laboratory Transfuse RBC
Peds Blood Product Infusion Order Set (386) [386] Blood product review will be performed unless exclusion criteria met. MD: Please note if transfusion giv en outside of parameter, please justify use in
More information2.5 Other Hematology Consult:
The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR
More informationClinical Implications of the Impact of Serum Tissue Factor Levels after Trauma
Clinical Implications of the Impact of Serum Tissue Factor Levels after Trauma Ian E. Brown, MD, PhD, and Joseph M. Galante MD, FACS Formatted: Font: 16 pt, Bold Formatted: Centered Formatted: Font: Bold
More informationTransfusion 2004: Current Practice Standards. Kay Elliott, MT (ASCP) SBB SWMC Transfusion Service
Transfusion 2004: Current Practice Standards Kay Elliott, MT (ASCP) SBB SWMC Transfusion Service Massive Transfusion Protocol (MTP) When should it be activated? Massive bleeding i.e. loss of one blood
More informationFinancial Disclosure. Objectives 9/24/2018
Hemorrhage and Transfusion Adjuncts in the Setting of Damage Control Joseph Cuschieri, MD FACS Professor of Surgery, University of Washington Adjunct Professor of Orthopedics and Neurosurgery, University
More informationTreating breakthrough bleeds: A new approach
Treating breakthrough bleeds: A new approach Using Bypassing Agents With HEMLIBRA Prophylaxis Indication HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes
More informationThe Bleeding Jehovah s Witness: A Nightmare Scenario?
The Bleeding Jehovah s Witness: A Nightmare Scenario? David Smith, Bristol Hospital Liaison Committee for Jehovah s Witnesses SW RTC: Bleeding in the Medical Patient - 21 February 2018 Jehovah s Witnesses
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationHEME 10 Bleeding Disorders
HEME 10 Bleeding Disorders When injury occurs, three mechanisms occur Blood vessels Primary hemostasis Secondary hemostasis Diseases of the blood vessels Platelet disorders Thrombocytopenia Functional
More informationEmergent Reversal of Oral Anticoagulation: Review of Current Treatment Strategies
AACN Advanced Critical Care Volume 25, Number 1, pp. 5-12 2014 AACN ECG Challenges Earnest Alexander, PharmD, and Gregory M. Susla, PharmD Department Editors Emergent Reversal of Oral Anticoagulation:
More informationMASSIVE TRANSFUSION PROTOCOL
MASSIVE TRANSFUSION PROTOCOL IF YOU ANTICIPATE EMERGENT NEED FOR LARGE AMOUNTS OF BLOOD IN A SHORT PERIOD OF TIME Call Blood Bank: 6622121 Tell them you have a patient who needs a Massive Transfusion and
More informationL iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche
L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche Armando Tripodi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Dept. of Clinical Sciences and Community Health University
More informationManaging Coagulopathy in Intensive Care Setting
Managing Coagulopathy in Intensive Care Setting Dr Rock LEUNG Associate Consultant Division of Haematology, Department of Pathology & Clinical Biochemistry Queen Mary Hospital Normal Haemostasis Primary
More informationBlood transfusion. Dr. J. Potgieter Dept. of Haematology NHLS - TAD
Blood transfusion Dr. J. Potgieter Dept. of Haematology NHLS - TAD General Blood is collected from volunteer donors >90% is separated into individual components and plasma Donors should be: healthy, have
More informationIndication Dosing Recommendation
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NovoSeven RT safely and effectively. See full prescribing information for NovoSeven RT. NovoSeven
More informationNovoSeven : Cleveland Clinic Guidelines by Pam Risko, Pharm.D.
Mandy C. Leonard, Pharm.D., BCPS Assistant Director, Drug Information Service Editor Meghan K. Lehmann, Pharm.D., BCPS Drug Information Specialist Editor Dana L. Travis, R.Ph. Drug Information Pharmacist
More information